Brachytherapy and radical prostatectomy in patients with early prostate cancer

Ferreira, Adriana Souza Sérgio; Guerra, Maximiliano Ribeiro; Lopes, Humberto Elias; Lima, U-Thant Mendonça; Vasconcelos, Yara Abrão; Teixeira, Maria Teresa Bustamante

doi:10.1590/1806-9282.61.05.431

Cited by 9 publications

(14 citation statements)

References 34 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with low-and intermediate-risk Pca, bRFS for patients receiving LDR was higher compared with patients, who had undergone RP; however, the result was not statistically significant, consistent with a recent study (29). Ferreira et al (30), reported 129 patients, who had undergone either brachytherapy (64 patients) or surgery (65 patients), and when stratified according to treatment, the survival time of patients who had undergone brachytherapy (79.70%) was higher compared with those who had undergone surgery (44.30%). Risk of bF was higher for surgery compared with brachytherapy (30).…”

Section: Discussionsupporting

confidence: 87%

“…Taussky et al (29), also reported that RP and LDR treatment did not result in significantly different outcomes at 4 years post-treatment, in patients with low-and low-intermediate-risk Pca. However, Ferreira et al (30) reported that the 5-year bRFS of patients with early Pca, who had undergone brachytherapy was significantly higher compared with those who had undergone surgery. Furthermore, Ciezki et al (24) reported that high-risk Pca treated with EBRT, LDR or RP yields efficacy with an improved bRFS for LDR and EBRT compared with RP (24).…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

125I low‑dose‑rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer

et al. 2019

View full text Add to dashboard Cite

Radical prostatectomy (RP) and low-dose-rate prostate brachytherapy (LDR) are two widely used treatment options for patients with T1c-T3a prostate cancer. In the present study, the efficacy of the two treatments was compared. A total of 429 patients who underwent either LDR (n=218) or RP (n=211) between January 2010 and June 2015 were retrospectively reviewed. Biochemical relapse-free survival time (bRFS) and clinical relapse-free survival time (cRFS) were assessed. The log-rank test compared bRFS between the two modalities, and Cox regression identified factors associated with bRFS. The median follow-up time and patient age were 46.6 months and 71 years, respectively. The bRFS at 1, 2 and 5 years was 89.4, 87.2 and 79.9% for LDR, respectively, and 91.0, 82.8 and 72.2% for RP, respectively (P=0.077). The cRFS at 1, 2 and 5 years was 99.1, 97.7 and 94.9% for LDR, respectively, and 99.0, 96.2 and 94.5% for RP, respectively (P=0.630). It was indicated that LDR produced equivalent bRFS and cRFS rates compared with RP. The risk of biochemical failure (bF) was higher for the RP group compared with the LDR group in patients with a Gleason score ≤3+4 (P=0.022) or initial prostate specific antigen ≤10 ng/ml (P=0.002). Based on the univariate and multivariate logistic regression analysis of all 429 patients, T stage ≥T2b was an independent predictor for bF.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 97%

125I low‑dose‑rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Despite these evidences, the biological mechanisms controlling cochlear gene expression driven by thyroid hormone receptor activity are still unknown. As already mentioned, the benign prostate hyperplasia combined with the increased ratio of the free/total PSA could be the result of the interaction between TBL1Y and thyroid hormone receptors, both expressed in the prostatic tissue [31,32].…”

Section: Discussionmentioning

confidence: 85%

TBL1Y: a new gene involved in syndromic hearing loss

et al. 2018

View full text Add to dashboard Cite

Hereditary hearing loss (HHL) is an extremely heterogeneous disorder with autosomal dominant, recessive, and X-linked forms. Here, we described an Italian pedigree affected by HHL but also prostate hyperplasia and increased ratio of the free/ total PSA levels, with the unusual and extremely rare Y-linked pattern of inheritance. Using exome sequencing we found a missense variant (r.206A>T leading to p.Asp69Val) in the TBL1Y gene. TBL1Y is homologous of TBL1X, whose partial deletion has described to be involved in X-linked hearing loss. Here, we demonstrate that it has a restricted expression in adult human cochlea and prostate and the variant identified induces a lower protein stability caused by misfolded mutated protein that impairs its cellular function. These findings indicate that TBL1Y could be considered a novel candidate for HHL.

show abstract

“…Taussky et al reported RP and LDR treatment did not result in signi cantly different outcomes at four years post-treatment in patients with low-and low-intermediate-risk Pca (26). However, Ferreira et al found the 5-year bRFS of patients with early Pca who had undergone LDR was signi cantly higher than those who had undergone surgery (27). Furthermore, Ciezki et al reported high-risk Pca treated with EBRT, LDR, or RP yields e cacy with better bRFS for LDR and EBRT compared with RP (21).…”

Section: Discussionmentioning

confidence: 99%

Treatment outcomes of 125I low-dose-rate brachytherapy vs radical prostatectomy for patients with intermediate-risk prostate cancer

Zhou¹,

Liang²,

Zhou³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Radical prostatectomy (RP) and low-dose-rate brachytherapy (LDR) are two widely used treatment options for patients with intermediate-risk prostate cancer (IRPC). However, which one is better remains controversial. Therefore, the purpose of this study was to compare the efficacy of RP vs LDR for patients with IRPC. Methods: A retrospective analysis was performed on 361 IRPC patients who underwent treatment from January 2010 and August 2017. 160 underwent RP and 201 underwent LDR using Iodine-125. Biochemical failure for RP was defined as prostate-specific antigen (PSA) levels > 0.2 ng/ml, and for LDR as nadir PSA level + 2 ng/ml. The log-rank test compared biochemical relapse-free survival (bRFS) between the two modalities, and Cox regression identified factors associated with bRFS. Results: Median follow-up was 54 months for RP and 69 months for LDR. The 5-and 8-year bRFS rates were 70.2% and 63.1% in the RP group, and 83.2% and 68.9% in the LDR group, respectively, P=0.003. There were no significant differences in terms of clinical relapse-free survival (cRFS), cancer-specific survival (CSS) or overall survival (OS) between the two groups. Conclusion: LDR is a reasonable treatment option for IRPC patients, yielding improved bRFS and equivalent rates of cRFS, CSS and OS compared with RP.

show abstract

Brachytherapy and radical prostatectomy in patients with early prostate cancer

Cited by 9 publications

References 34 publications

125I low‑dose‑rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer

125I low‑dose‑rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer

TBL1Y: a new gene involved in syndromic hearing loss

Treatment outcomes of 125I low-dose-rate brachytherapy vs radical prostatectomy for patients with intermediate-risk prostate cancer

Contact Info

Product

Resources

About